<DOC>
	<DOC>NCT00420134</DOC>
	<brief_summary>The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,. In this study the investigators try to separate mesenchymal stem cell from end stage liver disease, then these cells will be differentiated to progenitor of hepatocytes, finally , the investigators injected these cells into portal vein under ultrasound guide. The investigators determine the effects of injected cells in reestablishment of liver function.</brief_summary>
	<brief_title>Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>Inclusion criteria: MELD score of at least 10 Patent portal vein on color Doppler examination of the liver Normal alphafeto protein serum levels Age more than 18 Filling inform consent by patients and first degree family members Exclusion criteria: Any evidence of hepatocellular carcinoma on liver ultrasound studies Patients want to exclude from study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>end stage liver disease</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>stem cell therapy</keyword>
</DOC>